Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06749795
PHASE1

LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)

Sponsor: Liveome Inc.

View on ClinicalTrials.gov

Summary

A Phase 1b study to evaluate the safety and tolerability of LIV001 in Patients with Mild-to- Moderate Active Ulcerative Colitis

Official title: A Randomized, Double-Blind, Placebo Controlled, Multi -Center, Phase 1b Study to Evaluate the Safety and Tolerability of LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2025-03-24

Completion Date

2026-03-24

Last Updated

2025-03-24

Healthy Volunteers

No

Interventions

DRUG

LIV001

Orally administered for 8 weeks

DRUG

Placebo

Orally administered for 8 weeks

Locations (1)

Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska

Wroclaw, Poland